Italfarmaco, JCR Pharma Ink Deal for Hunter Syndrome Therapy
Italfarmaco and JCR Pharmaceuticals announced an exclusive license agreement for the development and commercialization of JR-141, an investigational therapy for Hunter Syndrome, in the United States, Europe, and Latin America.
Story updates
06:30:35 AM UTC
SquawkNews
JCR Pharmaceuticals signed an exclusive license with Italfarmaco to develop and, upon approvals, commercialize JR-141 for Hunter syndrome in the US, Europe, and Latin America. JCR will receive upfront, milestone, royalty payments and supply revenues.Material DetailsContext by AI AnalystThis is a la…